Per Aarsleff B (0REQ)
London Exchange · UK · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 666.50 |
|---|---|
| 52-week range | 635.50 – 910.00 |
| Return, 1 month / 3 months | −6.5% / −8.4% |
| Return, 1 year / 3 years | −12.3% / +133.8% |
| Trend | Below its 200-day average |
| RSI (14) | 39 |
| Volatility (1 year) | 30.5% |
| Worst drawdown (1 year) | -29.5% |
| Average daily value traded | 1.41M DKK |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Per Aarsleff is a Danish construction and engineering group based in Aarhus. It carries out civil engineering work such as pipelines, roads, bridges and marine projects, and it manufactures concrete piles and precast concrete elements through its own production. Its customers include public authorities, utilities and private developers, mainly in Denmark and neighbouring northern European markets, where the company takes on both large infrastructure contracts and smaller building and groundwork jobs.
Per Aarsleff B trades under the code 0REQ on the London Exchange in UK, with its price quoted in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Per Aarsleff B (0REQ) trades on the London Exchange in UK. It last closed at DKK 666.50 on 23 October 2026.
Its price-based Market X-Ray is 41 out of 100 (a weak price profile), ranking 2,602 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 12.3% and over the last three months it fell 8.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -12.1% | ||
| From 52-week high | -26.2% | ||
| Momentum | 30 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.4% | ||
| 6-month return | -14.2% | ||
| 12-month return, skipping the last month | -6.2% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.5% | ||
| Liquidity | 56 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.41M DKK | ||
| Zero-volume days | 5.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.7% |
|---|---|
| 1 month | −6.5% |
| 3 months | −8.4% |
| 6 months | −14.2% |
| 1 year | −12.3% |
| 3 years | +133.8% |
| 5 years | +167.3% |
Signals
| 50-day / 200-day average | 708.45 / 758.36 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 14.82 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Jan 2026 | DKK 12.0000 |
| 31 Jan 2025 | DKK 11.0000 |
| 30 Jan 2024 | DKK 10.0000 |
| 27 Jan 2023 | DKK 8.0000 |
| 1 Feb 2022 | DKK 8.0000 |
| 28 Jan 2021 | DKK 6.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.